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Abstract: The speciation of Cu2+, Ni2+ and Zn2+ ions in the presence of the fluoroquinolones 
(FQs) moxifloxacin, ofloxacin, levofloxacin and ciprofloxacin, in human blood plasma was 
studied under physiological conditions by computer simulation. The speciation was 
calculated using an updated model of human blood plasma including over 6,000 species 
with the aid of the program Hyss2009. The identity and stability of metal-FQ complexes 
were determined by potentiometric (310 K, 0.15 mol/L NaCl), spectrophotometric, 
spectrofluorimetric, ESI-MS and 1H-NMR measurements. In the case of Cu2+ ion the 
concentration of main low molecular weight (LMW) plasma complex (Cu(Cis)His) is very 
slightly influenced by all examined FQs. FQs show much higher influence on main plasma 
Ni2+ and Zn2+ complexes: (Ni(His)2 and Zn(Cys)Cit, respectively. Levofloxacin exhibits 
the highest influence on the fraction of the main nickel complex, Ni(His)2, even at a 
concentration level of 3 × 10−5 mol/L. The same effect is seen on the main zinc complex, 
Zn(Cys)Cit. Calculated plasma mobilizing indexes indicate that ciprofloxacin possesses the 
highest mobilizing power from plasma proteins, toward copper ion, while levofloxacin is 
the most influential on nickel and zinc ions. The results obtained indicate that the drugs 
studied are safe in relation to mobilization of essential metal ions under physiological 
conditions. The observed effects were explained in terms of competitive equilibrium 
reactions between the FQs and the main LMW complexes of the metal ions. 
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Elemental speciation in biological fluids, particularly human plasma, implies investigation of the 
association between the trace element and available bioligands: proteins and compounds with 
relatively low molecular weight (LMW). These investigations constitute a basis of metabolic and 
kinetic studies and are also used to explain the mobility, storage retention and toxicity of metal  
ions [1]. Chemical speciation of trace metals in human blood plasma has been discussed in several 
review articles [2,3], but the literature on speciation of metal ions in biological fluids, as a whole, is 
rather limited. There were two general approaches to the problem of metal speciation: the experimental 
one and by computer simulation. The experimental approach is focused on developing the instrumental 
methods for the determination of total and free metal ion concentrations, fraction bond to proteins and 
fraction of total metal distributed between various LMW ligands. However, since the most of the 
developed experimental methods considerably disturb the labile equilibria between metal ions and 
LMW ligands, they are not capable of accurately determining the very low levels of complex species 
concentrations existing in biological matrices [4]. Thus, biospeciation of trace metal ions is commonly 
studied by computer simulation. Two approaches are common: (a) minimization of total Gibbs-free 
energy of the multi-component system, subjected to the constraints of the elemental mass balance. This 
approach is used in geochemical and chemical engineering simulations; and (b) equilibrium 
calculations based on calculation of concentrations by solving the system of mass balance equations. 
This approach is often used in solution chemistry and requires knowledge of the identity and stability 
of all metal complexes presented in biological compartment (e.g. human plasma). The aim of the 
computer simulation of trace element distribution in human blood plasma is to calculate the relative 
percentages of all presented LMW complexes of metal ions and to assess their distribution under 
various conditions. This task is of great significance owing to the important role of these complexes in 
many physiological processes taking place in blood plasma. According to May et al. [5], trace metals 
in blood plasma may be classified into four fractions: (a) non-exchangeable i.e. tightly bound to the 
metaloproteins; (b) exchangeable, loosely bound by proteins; (c) complexed by LMW ligands; (d) free 
(hydrated) metal ions. To calculate the concentration of LMW complexes the binding constants of 
metal–protein complexes are required, but the relative percentage distribution of trace metal ions 
amongst the LMW ligands is not controlled by protein binding and so the metal protein equilibria can 
be bypassed in the plasma model [6]. 
Metal ions enter human body mainly from food and drink but their sources may also include 
industrial particulate matter, medicines, etc. In blood plasma, they are transported through specific 
intestinal and/or gastric channels in the form of free (aquated ions) or complexed species with various 
types of endogenous or exogenous ligands [7].  
Copper is an essential element which plays a critical role in human metabolism. Although, copper 
exists in both of its common oxidation states Cu2+ and Cu+, so far reported models of copper speciation 
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in human blood plasma have mainly focused on Cu2+ speciation. In blood plasma, 65% of the copper is 
irreversibly bond to ceruloplasmin (non-exchangeable), ~12% to transcuprein, ~12% is loosely bond to 
albumin, and a small amount is distributed amongst LMW complexes [8]. It is well established that 
mixed ligand ternary complexes with histidine are predominant. It was assumed by Ho at al. [9] and 
May et al. [5] that the total Cu2+ concentration in plasma is 1.6× 10−11 mol/L and free concentration is 
5.1 × 10−16 mol/L. 
Nickel is an essential constituent of methyl-CoM reductase, CO dehydrogenase and hydrogenase in 
some strains of bacteria. Its physiological role in human organism is not yet fully elucidated. It is 
capable of activating or inhibiting a number of enzymes, altering cell membrane properties and influencing 
various redox processes. The main carrier proteins of nickel in serum are albumin and nickeloplasmin, but 
it can also be bound to α-2-macroglobulin. Plasma concentration is 10−7–10−9 mol/L and free 
concentration in plasma is ~1.0 × 10−11 mol/L. Of all LMW ligands, nickel is most strongly bound  
to histidine [10]. 
Zinc is an essential trace element whose total concentration in blood plasma is 1.6 × 10−5 mol/L and 
free concentration 10−9 mol/L. Zn2+ is rigidly bound to α-2-macroglobulin and as exchangeable fraction 
to albumin and serum transferrin. Its main LMW complex is with cysteine and ternary complexes with 
cysteine and histidine [11].  
Fluoroquinolones (FQ) are synthetic antibacterial agents which could act as the competitive LMW 
ligands for trace metal ions in blood plasma [12–14]. They may remove metal ions from their protein 
complexes and compete with other naturally occurred ligands in blood plasma for metal binding.  
Its relative ability to compete for metal ions in blood plasma can be assessed in terms of the plasma 
mobilizing index (PMI) proposed by May and Williams [15]. The PMI may be used to determine 






(ா௅)  is the total concentration of the LMW metal ion fraction in the presence of exogenously 
administered chelating agents and ௅ܶெௐ is the total concentration of the LMW metal ion fraction in 
normal plasma. The PMI may serve to compare mobilizing power of various ligands toward particular 
metal ion. It permits assessment of the capacity of exogenous ligand to increase the amount of the 
LMW metal ion fraction at the expense of the protein bound metal. The percentage distribution of 
metal ions in the LMW fraction is computed assuming that the metal-protein complex is buffer free 
metal ion concentrations in plasma. 
Based on our previously described blood plasma model [16], the aim of the present work was to 
establish the ability of some members of fluoroquinolone antibacterial agents to mobilize trace metal 
ions from blood plasma. The obtained data are essential for elucidating the mechanism of action of 
fluoroquinolones and the influence of metal ions on this mechanism. In addition the obtained results 
may be used to assess the safety of FQs toward mobilization of metal ions and consequent change of 
their metabolic pathways. 
In this work we studied the effect of a number of FQs (ciprofloxacin-Cipro, ofloxacin-Oflo, 
levofloxacin-Levo and moxifloxacin-Moxi) on the biodistribution of Cu2+, Ni2+ and Zn2+ ions using the 
equilibrium calculations method. The goal of this investigation was to evaluate the capacity of some 
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fluoroquinolone antibacterial agents to influence the LMW metal ions fraction in plasma and 
rationalize their ability to compete for metal ions with endogenous plasma ligands. 
2. Results and Discussion 
2.1. Potentiometric and Spectrophotometric Measurements 
The protonation equilibria of FQ anions were studied before complexation measurements using 
both potentiometry and spectrophotometry, under the same conditions as used in the complexation 
study. The complex formation constants between metal cations (Cu2+, Ni2+ and Zn2+) and quinolones 
were investigated by emf titrations in 0.15 M (NaCl) solution at T = 310 K. Representative titration 
curves obtained for solutions containing moxifloxacin and metal cations are illustrated in Figure 1. 
Figure 1. Titration curves for moxifloxacin and moxifloxacin + metal cations with NaOH 
at 310 K and I = 0.15 M (NaCl). Concentration of metal cations: 1.0 mmol/L, concentration 
of moxifloxacin: 2.0 mmol/L. 
 
The pH titration of moxifloxacin in diprotonated form shows that the two protons dissociate in 
individual steps at a = 1–2 and a = 2–3 corresponding to the dissociation of the carboxyl and amine 
groups, respectively. The titration parameter a represents the number of moles of strong base added per 
mole of quinolone and was calculated through the formula: 
ܽ = ܥே௔ைு ேܸ௔ைு − ଴ܸܥு஼௟
଴ܸܮ  (2)
where V0 and L are the initial volume and concentration of fluoroquinolone in the titrated solution. 
Below a = 1 strong acid (HCl) is titrated. It can be seen that moxifloxacin is present in solution in the 
whole titration range. In the presence of metal cations the titration curves are shifted due to the 
formation of metal complexes. These curves showed that complex formation begins from a low pH 
value and mainly occurs in the deprotonation region of the carboxyl group of moxifloxacin.  
The titration curves patterns of other FQs were similar to those of moxifloxacin. Precipitation was 
observed at pH values between pH 7–8. When precipitates formed the titrations were stopped and the 
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To complement potentiometric measurements, spectrophotometric data were also obtained for 
metal-quinolone systems. The UV spectra in the presence of the metal cations of all FQs studied were 
always compared with the corresponding UV spectra of the free FQs. Spectral measurements of metal 
(II) + FQ solutions show evidence of an intensive higher energy band situated between 285 and 295 
and lower energy broad band between 320 and 380 nm for all M2+ + FQ systems (Figure 2).  
Upon increasing the pH from 3 to 9 the higher energy band shows only small changes in position and 
maximum intensity (hypsochromic shift). The lower energy band exhibits however, significant 
changes in a shape, position and intensity (bathochromic shift). Wavelengths of maximum absorptions 
of free quinolones and metal-quinolones solutions are given in Table 1. In comparison with the free FQ 
spectra, the higher energy band may be attributed to fluoroquinolone nucleus while the lower energy 
band may be attributed to metal carbonyl and metal carboxyl bonds overlapping absorption. The 
presence of isosbestic points can be attributed not only to equilibria between protonation forms of the 
ligand but also proved that the different complexes were formed in solution. In the presence of metal 
ion, in comparison with the spectrum of fluoroquinolone alone, all bands are shifted toward higher 
wavelengths (Table 1).  
Figure 2. UV-Vis spectra of Cu2+-moxifloxacin solutions against free moxifloxacin as a 
blank. (CCu = 2.5 × 10−5 mol/L, CMoxi =5 × 10−5 mol/L, I = 0.15 mol/L NaCl, T = 310 K). 
 
Table 1. Maximum UV absorption of fluoroquinolones and their complexes at pH = 7.4. 
 λ1max (nm) λ2max (nm) 
Moxifloxacin 289 340 
Cu-Moxi 292 336 
Ni-Moxi 288 340 
Levofloxacin 288 332 
Cu-Levo 292 326 
Ni-Levo 288 330 
Stability constants were calculated with Hyperquad2006 suite of programs [17]. To find the model 
that gives the best fit to the experimental data, various complexes and combinations thereof were 
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proton concentration) were held constant. The pure hydrolytic complexes and protonated fluoroquinolone 
species were not refined during the calculations. First, the potentiometric and spectrophotometric data 
were separately calculated until the best set of complexes was found. For spectral data the program 
pHab was utilized. Then both kinds of data were treated together in Hypequad2006. The calculated 
protonation constants are presented in Table 2. The calculated overall stability constants of complexes 
are given in Table 3. 
They are in good agreement with so far published data. From Table 3 it can be seen that in all systems 
M(FQH)2+ and M(FQ)20 complexes were found. Overall stability constants of fluoroquinolones with 
these divalent metal ions follow the Irving-Williams series as expected (Cu ≥ Ni > Zn). 
Table 2. Calculated protonation constants (logβ ± SD) for fluoroquinolones compared with 
literature values. 
FQ Methods logβ1H logβ2H Ionic Medium T °C Reference 
Cipro 
UV/POT 8.81 14.71 0.15M NaCl 37 this work 
POT 8.95 15.10 0.1M NaCl 25 [18] 
UV 8.89 14.79 0.05M NaAc 25 [19] 
UV 8.73 14.91 0.2 M NaCl 25 [20] 
UV 8.84 15.17 / / [21] 
POT 7.41 13.55 0.1M NaNO3 / [22] 
POT 8.62 14.71 0 25 [23] 
Oflo 
UV/POT 8.27 14.31 0.15M NaCl 37 this work 
POT 8.60 14.70 0.1M NaCl 25 [18] 
UV 7.18 / / / [24] 
POT 8.28 14.38 / / [24] 
UV 8.28 14.25 0.05NaAc 25 [19] 
POT 8.11 14.16 0 25 [23] 
POT 7.88 / 0.1M NaNO3 / [23] 
Moxi 
UV/POT 9.27 15.58 0.15M NaCl 37 this work 
POT 9.53 15.76 0.1 M NaCl / [18] 
POT 9.29 15.54 0.15 M NaCl / [25] 
UV 8.72 14.88 / 25 [26] 
POT 9.53 15.76 0.1M NaCl 25 [27] 




UV 9.3 15.57 0.1 M LiCl 25 [29] 
POT 9.34 15.67 0.1 M LiCl 25 [29] 
Levo 
UV/POT 7.90 13.68 0.15M NaCl 37 this work 
POT 8.15 14.17 0.1M NaCl 25 [18] 
POT 8.15 14.17 0.1MNaCl 25 [30] 
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Table 3. Calculated overall stability constants (logβpqr ± SD) for complexes present in  
M2+-FQ (MpFQqHr) systems at physiological conditions (T = 37 °C and I = 0.15 M NaCl). 
Cu-FQ 
p q r Ciprofloxacin Levofloxacin Ofloxacin Moxifloxacin 
1 1 1 14.89 ± 0.22 13.74 ± 0.04 14.21 ± 0.03 15.77 ± 0.03 
1 2 −1 6.13 ± 0.21 1.66 ± 0.06 1.88 ± 0.04 6.71 ± 0.04 
1 2 0 16.06 ± 0.11 11.08 ± 0.03 11.31 ± 0.02 12.92 ± 0.02 
1 2 1 22.6 ± 0.22 19.18 ± 0.04 19.42 ± 0.03 23.51 ± 0.03 
1 2 2 29.06 ± 0.15 26.25 ± 0.03 26.56 ± 0.03 29.89 ± 0.03 
statistics 
s = 1.87 s = 0.54 s = 0.78 s = 1.23 
χ2 = 12.46 χ2 = 5.46 χ2 = 3.54 χ2 = 5.49 
Ni-FQ 
p q r Ciprofloxacin Levofloxacin Ofloxacin 
Moxiflox
acin 
1 1 1 14.92 ± 0.22 13.76 ± 0.04 16.61 ± 0.03 12.72 ± 0.03 
1 2 −1 6.32 ± 0.21 8.48 ± 0.06 8.84 ± 0.04 4.62 ± 0.04 
1 2 0 16.95 ± 0.11 16.3 ± 0.03 16.62± 0.02 13.87 ± 0.02 
1 2 1 22.34 ± 0.22 23.89 ± 0.04 24.23 ± 0.03 19.52 ± 0.03 
1 2 2 28.98 ± 0.15 29.18 ± 0.03 29.58 ± 0.03 27.54 ± 0.03 
statistics 
s = 1.47 s = 0.93 s = 1.28 s = 1.03 
χ2 = 11.21 χ2 = 4.43 χ2 = 2.57 χ2 = 7.52 
Zn-FQ 
p q r Ciprofloxacin Levofloxacin Ofloxacin Moxifloxacin 
1 1 1 12.74 ± 0.22 14.2 ± 0.04 12.9 ± 0.03 12.47 ± 0.03 
1 2 0 10.49 ± 0.11 9.68 ± 0.03 9.08 ± 0.02 10.56 ± 0.02 
1 2 1 17.82 ± 0.22 18.04 ± 0.04 17.21 ± 0.03 17.95 ± 0.03 
1 2 2 24.84 ± 0.15 24.26 ± 0.03 23.87 ± 0.03 24.91 ± 0.03 
statistics 
s = 0.97 s = 1.55 s = 1.18 s = 1.83 
χ2 = 12.46 χ2 = 6.41 χ2 = 6.34 χ2 =3.92 
2.2. Reliability of the Data 
In Hyperquad2006 program the quality of the fit was evaluated using the set of statistical 
parameters, U, χ2, s and σ [17]. The calculated set of statistics generally indicate good overall fit of the 
experimental data. In addition the residuals in potentials were analyzed for normal probability 
distribution autocorrelations and systematic trends. Inspections of the residuals in potentials for the 
metal-FQ model that fits best experimental data shows a linear normal probability plot and a small 
autocorrelation length. Examination of the residuals scatter reveals that no significant systematic trends 
exist, so the accepted set of complexes and their stability constants gives a plausible explanation of the 
experimental data. Similar results were obtained with analysis of absorbance residuals. 
Existing literature data on stability constants of the studied metals with some fluoroquinolones in 
different media and temperature ranges are given in Table 4. Comparing our and literature models 
reasonably good agreement is evidenced. Complexes (111), (122), (121), (120) and (12−1) were found 
in all studied systems except in Zn-FQ systems where (12−1) was not found. The complex (1,1,0) has 
not been found in our calculations and the (1,3,2) complex of nickel with ciprofloxacin was not found 
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either. The stability constants of 1:1 and 1:2 complexes (metal to ligand) are moderately high. Owing 
to the low total concentrations of metals and ligands no polynuclear complexes were found. However, 
protonated and hydrolytic complexes are common for all systems. The proton probably resides on 
secondary or tertiary nitrogen in C-7 substituent, while hydrolytic species originate from the protolysis 
of coordinated water. The complex [M(FQ)2H2] possesses logβ in the range ca. 26‒29 for Cu and Ni 
ions while with Zn ion logβ is considerably smaller. 
Table 4. Literature overview of stability constants of the complexes Mp(FQ)qHr calculated 
from potentiometric measurements data of M(II)-FQ systems (I = ionic strength of the 
medium, mol/L). 
Metal Ion FQ p q r logβpqr I T (°C) Reference 
Cu 
Oflo 
1 1 1 12.34 
0.1 NaCl 25 * Gameiro et al. [31] 
1 2 2 23.4 
1 1 1 14.21 
0.1 NaCl 
22 Urbaniak et al. [32] 
1 2 2 26.56 
1 2 1 19.42 
1 2 0 11.31 
1 2 −1 1.88 
1 1 1 14.84 
25 * Feio et al. [18] 
1 2 2 28.40 
Cipro 
1 1 0 6.2 
0.15 NaCl
25 
Wallis et al. [33] 
1 1 0 6.1 37 
1 2 0 11.1 25, 37 
1 2 −1 4.0 25 
1 2 −1 4.5 37 
1 1 1 14.73 
0.2 KCl 25 Turel et al. [34] 1 2 2 28.53 
1 2 1 21.93 
1 1 1 14.43 
0.1 NaCl 25 * Feio et al. [18] 1 1 0 6.46 
1 2 0 11.77 
1 1 1 14.89 
0.1 NaCl 
22 Urbaniak et al. [32] 
1 2 −1 6.13 
1 2 0 16.06 
1 2 1 22.60 
1 2 2 29.06 
Levo 
1 1 1 13.74 
1 2 −1 1.66 
1 2 0 11.08 
1 2 1 19.18 
1 2 2 26.25 
1 1 1 14.37 
25 * Feio et al. [18] 
1 1 0 7.13 
1 2 2 27.22 
1 2 0 11.78 
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Table 4. Cont. 
Metal Ion FQ p q r logβpqr I T (°C) Reference 
 Moxi 
1 1 1 15.54 
   
1 1 0 8.21 
1 2 2 31.30 
1 2 0 14.17 
1 1 1 14.21 
1 1 0 10.20 
1 2 2 27.73 
1 2 0 22.17 
Ni 
Oflo 
1 1 1 13.42 
1 1 0 5.91 
1 2 2 25.60 
Cipro 
1 1 1 13.41 
1 1 0 7.43 
1 1 1 12.93 
0.2 KCl 25 
Turel et al. [34] 
1 2 2 25.77 
1 2 1 18.42 
1 3 2 29.7 
Zn 
1 1 1 12.32 
0.2 KCl 25 1 2 2 24.72 
1 2 1 17.41 
1 1 1 12.74 
0.1 NaCl 
22 Urbaniak et al. [32] 
1 2 0 10.49 
1 2 1 17.82 
1 2 2 24.84 
Oflo 
1 1 1 14.64 
1 2 0 10.51 
1 2 1 18.36 
1 2 2 24.40 
Levo 
1 1 1 12.90 
1 2 0 9.08 
1 2 1 17.20 
1 2 2 23.87 
Oflo 
1 1 1 12.67 
25 * Feio et al. [18] 1 1 0 5.23 
1 2 2 24.48 
* Values of stability constants were recalculated taking into account M, H and L as components instead of M 
and HL as given in the original reference. 
2.3. Solution Equilibria and Distribution Diagrams 
The distribution of various complexes in M(II)-FQ solutions are shown in Figures 3–5. In the 
following text the complexes are designated with an acid HMoxi as a component to make the 
mechanisms meaningful. HMoxi may be either neutral or a zwitterion, the latter being more probable. 
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As can be seen from Figure 3, at lower pH values (less than 3), hydrated copper ion exists dominantly 
in solution. With increasing pH values over 3 the formation of Cu(HMoxi)2+ complex (Cu(Moxi)H on 
the distribution diagram) starts, probably according to the reaction: 
Cuଶା + HMoxi଴ ↔ [Cu(HMoxi)]ଶା (3)
with the maximum concentration at pH = 4. This complex upon increasing pH, binds another molecule 
of moxifloxacin and gives [Cu(HMoxi)2]2+ complex (Cu(Moxi)2H2 on the distribution diagram) with 
maximum concentration at pH ~6, by the reaction: 
[Cu(HMoxi)]ଶା + HMoxi଴ ↔ [Cu(HMoxi)ଶ]ଶା (4)
Figure 3. Distribution diagram of Cu-moxifloxacin species at ligand-to-metal concentration 
ratio 2:1 and total metal concentration 1.0 mmol/L.  
 
Figure 4. Distribution diagram of Ni-moxifloxacin species at ligand-to-metal concentration 
ratio 2:1 and total metal concentration 1.0 mmol/L.  
 
Cu-Moxif loxacin1:2
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Figure 5. Distribution diagram of Zn-moxifloxacin species at ligand-to-metal concentration 
ratio 2:1 and total metal concentration 1.0 mmol/L. 
 
At pH values above 6.5 this complex releases protons and gives the mixed complex 
[Cu(HMoxi)Moxi]+ (Cu(Moxi)2H on the distribution diagram) with a maximum concentration at pH 
values close to physiological. Further pH increases lead to the release of another proton and formation 
of [Cu(Moxi)2(OH)] species (Cu(Moxi)2H−1 on the distribution diagram) at pH > 8. The complex 
[Cu(Moxi)2]0 is a minor species between pH value 7.5–8.5. The overall complex reaction follows  
the scheme: 







Copper(II) ion exhibits characteristic coordination numbers 4, 5 and 6. In the [Cu(HMoxi)2]2+ 
complex, according to X-ray data [35], moxifloxacin acts as a bidentate O,O-ligand with probable 
formation of a six-membered ring by the 4-keto and 3-carboxyl oxygens [36–40]. It may be assumed 
that one or two additional coordination sites in the copper coordination sphere are occupied with water 
molecules. One of water molecules is more strongly bound to Cu2+ ion and is subject to hydrolysis 
upon increasing the pH. The other water molecule hydrolyzes at pH > 11 and this leads to the onset  
of precipitation. 
Figure 4 represents the distribution of moxifloxacin species in solution in the presence of nickel. 
Obvious dominant species are those of the ML2 type. [Ni(HMoxi)2]2+ complex (Ni(Moxi)2H2 on the 
distribution diagram) forms in the pH 4–7 range with the maximum concentration at pH = 6 and 
neutral complex [Ni(Moxi)2]0 in pH range 6–10 with maximum concentration at pH = 8. The complex 
[Ni(Moxi)2]0 is very stable in the 7.0–9.0 pH range and is probably formed in plasma under 
physiological conditions. The complexation behavior of moxifloxacin toward nickel is important for 
understanding the antibacterial action of the drug against metal-dependent microorganisms.  
For example, Helicobacter pylori (H. pylori) is a common human pathogen responsible for various 
Zn-Moxif loxacin 1:2
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gastric diseases. This bacterium produces urease and hydrogenase to survive in the acidic environment 
of the stomach. Nickel is an essential cofactor for urease and hydrogenase. H. pylori has to uptake 
sufficient nickel ions [41] for the maturation of urease, and on the other hand, to prevent the toxic effects 
of excessive nickel ions. Moxifloxacin was recently found to be effective against H. pylori. By binding 
the Ni2+ into a strong Ni-Moxi complex, moxifloxacin acts as safe and strong Helicobacter pylori 
eradicator [42]. 
The distribution diagram of species in the Zn2+-moxifloxacin system, for the concentration ratio 
[Moxi]/[Zn] = 2:1 is shown in Figure 5. As can be seen from Figure 5 the dominating complexes in a 
wide pH range are [Zn(HMoxi)]2+ (Zn(Moxi)H on the distribution diagram) and [Zn(Moxi)2]0, with the 
maximum concentrations at pH 6 and ca. 9, respectively. These complexes may be formed via the 
same reaction mechanism as in case of copper and nickel ions. In the pH range 5.5–8.5 the complexes 
[Zn(HMoxi)2]2+ (Zn(Moxi)2H2 on the distribution diagram) and [Zn(HMoxi)(Moxi)]+ (Zn(Moxi)2H on 
the distribution diagram) occur to a lesser extent. Hydrolytic species of Zn2+ disturb the complexation 
considerably. Micro-colloidal precipitated ZnH-2 is dominant at pH > 9. Similar species distribution 
results were obtained for the other M-FQ systems. 
2.4. Fluorescence Measurements 
Spectrofluorimetric titrations were carried out by addition of known quantities of metal ion 
(concentration range (0–1) × 10−3 mol/L) to 2 × 10−5 mol/L buffered solutions of the ligand. 
The wavelenght of excitation was 292 nm (for levofloxacin). Fluorescence spectra of levofloxacin 
in the absence and the presence of copper ion are presented in Figure 6. From the figure a decrease of 
fluorescence intensity upon addition of copper ion can be seen. The maximum emission of 
levofloxacin occurs at 482 nm and it shifts hypsochromically slightly upon addition of copper.  
Figure 6. Fluorescence emission spectrum of levofloxacin (2 × 10−5 mol/L, λex = 292 nm) 
in aqueous solution at pH 7.4 in the presence of Cu(II) ions (concentration range of Cu ion: 
























↓addition of Cu(II) ions
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To examine the fluorescence quenching mechanism a Stern-Volmer plot was used and presented in 
Figure 7. 
F଴
F = 1 + ܭௌ௏[ܯ] (6)
where F0 and F are the fluorescence intensity in the absence and the presence of the quencher, 
respectively and [M] is the concentration of the metal ion [43]. From the slope of the Stern-Volmer 
plot, the Stern-Volmer constant can be determined. The obtained value was KSV = 1.82 × 104 or  
logKSV = 4.26. Fluorescence quenching typically occurs through either static or dynamic quenching 
mechanisms. The static quenching results in a linear relationship between (F0/F) and concentration of 
metal ion. This result suggests that levofloxacin fluorescence quenching in the precense of copper ion 
was probable static quenching as a result of the formation of a non-fluorescent complex between the 
fluorophore and the quencher.  
Figure 7. Stern-Volmer plot for the quenching of levofloxacin by copper ion.  
 
Stability constant determination. The complexation of a metal ion Cu2+ by a ligand levofloxacin in 
solution can be represented by the cumulative equilibria: 
M+ L ↔ ML (7)
M+ 2L ↔ MLଶ (8)
with the association constant K: 
K୬ =
[ML]
[M][L]௡ ; n =1,2 (9)
expressing the degree of stability of the complex in the given solvent and temperature conditions. The 
stability constants of the formed complexes can be calculated from the double reciprocal plot: 
For 1:1 complex:  
1
ܨ଴ − ܨ =
1
(ܨை − ܨஶ)ܭଵܥெ +
1
ܨை − ܨஶ (10)
And for 1:2 complex:  
1
ܨ଴ − ܨ =
1
(ܨை − ܨஶ)ܭଶܥெଶ +
1
ܨை − ܨஶ (11)










Cu(II) concentration (mol L-1)
0                  2                     4                     6                    8                  10   (×10-4)
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where F0 and F are the fluorescence intensity of ligand in the absence of metal ion and fluorescence 
intensity of solution at each metal concentration, respectively [44,45]. F∞ is the fluorescence intensity 
when fluorescence of the solution remains constant with further addition of metal ion. K1 and K2 are 
the stability constants of the formed complexes. When 1/(F0 − F) is plotted against CM−1 or CM−2 
(Figure 8) the stability constant is calculated by the ratio intercept/slope. The formation stability constant 
for these complexes calculated to be logK1 = 4.23 and logK2 = 8.19 or logβ1 = 4.23 and logβ2 = 12.42. 
These values are very close to those calculated by potentiometric and spectrophotometric measurements. 
Figure 8. Double reciprocal plot obtained from 1/(F − F0) plotted against: (a) 1/CM and (b) 1/CM2. 
 
Consideration of the Inner Filter Effect 
UV absorbance spectra demonstrate that FQs and their metal complexes strongly absorb at 292 nm, 
the excitation wavelenght of FQs. The attenuation of the excitation beam due to such absorption results 
in a fluorescence intensity decrease know as the inner filter effect [46]. Since absorbtion is high 
correction was aplied to all our fluorescence data. The corection factor CF was calculated according to 
Parker and Barnes equation [47]: 




where F0 is the corrected fluorescence, F is the observed fluorescence and Ax is the optical density of 
the solution at excitation wavelength; lx and ∆lx are geometrical parameters of the fluorimetric cell. 
The lx was calculated according to formula lx = (1 − ∆lx)/2. ∆lx was set as 0.250 cm corresponding to  
10 nm bandwidth [48]. The calculated correction factor was in the range 1.50–1.73. 
2.5. H1-NMR Measurements 
To extend the speciation study some NMR spectra of the studied systems were recorded. The NMR 
experimental conditions were so chosen to make speciation unambiguous. Proton NMR spectra of 
levofloxacin and Zn2+ + levofloxacin at different molar ratios are shown in Figure 9.  
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Figure 9. 1H-NMR spectra of Zn(II)-levofloxacin complexes at various mole ratios of the 
ligand and zinc salt in DMSO-d6 solution recorded at 200 MHz. 
 
The signals for aryl protons (doublet at 7.52 (C-5) and singlet at 8.92 ppm (C-2)), oxazine protons 
(4.31–4.90 ppm) and methyl group protons attached to oxazine ring (doublet at 1.43 ppm) are 
practically unchanged after the addition of different amounts of zinc(II)-chloride. This indicates that 
they are situated far from the binding site. However, two groups of the piperazine signals as well as the 
methyl protons of the piperazine nitrogen appeared at significantly higher δ-values in all 1H-NMR 
spectra of the zinc(II)-complexes. This strong downfield shift for the piperazine methyl group  
(0.56 ppm), 3',5'-piperazine protons (0.79 ppm) and 2',6'-piperazine protons (more than 0.3 ppm, 
overlapped with the water peak) indicates that the piperazine nitrogen atoms are coordinated to the 
zinc (Figure 9). A tentative structure of the complex may be represented as in Figure 10.  
Figure 10. Proposed structure for Zn(II)-levofloxacin complex. 
 
Addition of Zn2+ into a D2O solution of levofloxacin at pH = 6.0 (mole ratio: Zn to Levo= 1:1 and 
2:1) produces C-2 proton shift toward lower field (Table 5). Most other proton signals are also shifted 
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downfield in comparison with free ligand protons. It may be concluded that zinc is coordinated to the 
carboxylate and 4-carbonyl oxygen in D2O as reported in many papers [36–40]. Thus, the binding sites 
of Zn2+ ion in D2O are different from those in DMSO-d6. The difference may be attributed to the 
different polarity of these molecules. 
Table 5. 1H-NMR chemical shifts of Levo and Levo + Zn2+ (concentration ratio 1:1 at pH = 6.0). 
Levo-proton δ (free) δ (complex) ∆δ a 
H-2 8.34 8.51 0.17 
H-5 7.24 7.25 0.01 
H-1a, 1b 4.36–4.61 4.38–4.64 0.01 
H-3', 5' 3.50 3.61 0.11 
H-2', 6' 3.38 3.46 0.08 
H-4'a 2.95 2.99 0.04 
H-1c 1.44 1.43 0.01 
a ∆δ = δ(complex) − δ(free). 
2.6. ESI-MS Measurements 
To further confirm the speciation derived from potentiometric and spectrophotometric 
measurements ESI-MS measurements were made on fluoroquinolone-metal ion solutions. The 
experimental conditions were adjusted in such a way that the fragmentation is minimal. Several time 
repeated measurements resulted in nearly the same spectra, indicating that the obtained signals belong 
to species formed in solutions rather than in gas plasma. The most intensive signals can be attributed to 
the 1:1 and 1:2 (metal to ligand) complexes. Signals arising from fragmentation can be explained 
either by CO2 or H2O loss. Loss of HF was not observed. The ESI-MS data of M-FQ solutions with 
FQ to metal concentration ratio 2:1 at pH 4.5 show evidence to formation of the complex M(FQ) and 
M(FQ)2 as shown in Tables 6–8, and in Figure 11.  
Table 6. Experimental and theoretical m/z values of ESI-MS spectra in  
Copper-fluoroquinolone solution at pH = 4.5; ((m/z)e and (m/z)t denote experimentally 
determined and calculated value, respectively). 
  Complex  
Fluoroquinolone 
[ML]+ [ML2]+ [M2L3]+ 
(m/z)e (m/z) t (m/z)e (m/z) t (m/z)e (m/z) t 
Moxifloxacin 464.3 463.9 865.0 864.8 1327.7 1327.3 
Ofloxacin 425.1 424.9 784.2 784.2 - - 
Levofloxacin 425.0 424.9 - - - - 
Ciprofloxacin - - 724.1 724.2 - - 
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Table 7. Experimental and theoretical m/z values of ESI-MS spectra in Zinc-fluoroquinolone 





(m/z)e (m/z)t (m/z)e (m/z) t 
Moxifloxacin 466.1 465.7 - - 
Ofloxacin  425.2 424.9 - - 
Levofloxacin - - 786.4 786.0 
Ciprofloxacin - - 726.0 725.9 
Table 8. Experimental and theoretical m/z values of ESI-MS spectra in  





(m/z)e (m/z)t (m/z)e (m/z)t 
Moxifloxacin 459.2  459.0 859.6 859.9 
Ofloxacin  419.5 419.2 - - 
Levofloxacin - - 778.9 779.3 
Ciprofloxacin 389.6 389.1 719.5 719.4 
Figure 11. ESI-MS spectrum of Cu-moxifloxacin solution at pH = 4.5. 




















2.7. Influence of Fluoroquinolones on Bio-Speciation of Copper, Nickel and Zinc Ions in Human  
Blood Plasma 
The LMW bio-distributions of Cu(II), Zn(II) and Ni(II) ions in the presence of fluoroquinolone in 
blood plasma were computed using the HySS2009 program. The total concentrations of physiological 
plasma ligands and metals were as described in our previous paper [16]. Average maximum 
concentration of quinolones in human plasma is ca. 2 × 10−5 mol/L. 
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Table 9. Calculated bio-distribution of dominant Cu(II) species (%) in human blood 
plasma in the presence of fluoroquinolones. 
Cu-LMW Species 
Concentration of Fluoroquinolone (mol/L) 
0 1 × 10−5 1 × 10−4 1 × 10−3 
Moxifloxacin 
CuCisHis 25.0 23.9 23.9 22.7 
CuHCisHis 15.8 15.1 15.1 14.3 
CuHis2 10.7 10.2 10.2 9.7 
CuHisSer 6.8 6.5 6.5 6.1 
CuHisThr 6.0 5.8 5.8 5.5 
CuHHisLys 4.5 4.3 4.3 4.1 
 Ciprofloxacin 
CuCisHis 25.0 25.0 24.9 20.8 
CuHCisHis 15.8 15.7 15.7 13.2 
CuHis2 10.7 10.7 10.7 8.9 
CuHisSer 6.8 6.7 6.7 5.6 
CuHisThr 6.0 6.0 6.3 5.0 
CuHHisLys 4.5 4.5 4.5 3.7 
 Ofloxacin 
CuCisHis 25.0 25.0 25.0 25.0 
CuHCisHis 15.8 15.8 15.8 15.8 
CuHis2 10.7 10.7 10.7 10.7 
CuHisSer 6.8 6.8 6.8 6.7 
CuHisThr 6.0 6.0 6.0 6.0 
CuHHisLys 4.5 4.5 4.5 4.5 
CuCisHis 25.0 25.0 25.0 25.0 
CuHCisHis 15.8 15.8 15.8 15.8 
 Levofloxacin 
CuHis2 10.7 10.7 10.7 10.7 
CuHisSer 6.8 6.8 6.8 6.7 
CuHisThr 6.0 6.0 6.0 6.0 
CuHHisLys 4.5 4.5 4.5 4.4 
2.7.1. Copper in Human Blood Plasma Model 
The concentration of free copper is taken as 1 × 10−19 mol/L. The major LMW complexes of copper 
ion in plasma at normal physiological conditions (no exogenous ligand addition) were computed and 
are shown in Table 9 (first column). At ligand concentrations of less than 1 × 10−4 mol/L the fraction 
of main copper complexes remains unchanged. In the case of ciprofloxacin, however, a small change 
in the fraction of dominant Cu-LMW species at ligand concentrations 1 × 10−5–1 × 10−4 mol/L is seen 
(Table 9). With increasing ligand concentration to 1 × 10−3 mol/L only moxifloxacin and ciprofloxacin 
influence the fraction of Cu-LMW species considerably. Thus, these fluoroquinolones appear as 
competitive ligands to amino acids. Upon further increasing the ligands concentration to 1 × 10−2 mol/L 
fractions of main LMW complexes continue to decrease until, in the extreme case, the complexes of 
Cu-FQ appear. Normal level of FQs in blood plasma after a single dose of a 500 mg tablet 
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administration is ca. 10−5 mol/L [49]. This peak concentration lasts for about 2–3 h and then begins to 
fall. Considering the plasma life of FQs is long enough to establish a local equilibrium, competitive 
reactions between LMW complexes of copper ion and FQs may occur. Thus, a fraction of copper may 
be bound to the FQs. It is well known that metal–FQ complex species alter the properties of the FQ in 
terms of bioavailability and antimicrobial action [50]. As illustrated in Figure 12, increasing the 
plasma concentration of FQ increases the fraction of mobilized copper. It may provide an additional 
explanation of the mechanism of FQ action with respect to the role of essential metal ions. 
Figure 12. Dominant Cu-Cipro species in blood plasma in the presence of ciprofloxacin (Cip). 
 
The PMI curves of copper ion with the studied fluoroquinolones are shown in Figure 13. It can be 
seen that ciprofloxacin has the highest mobilizing effect. The effects of ofloxacin and levofloxacin do 
not differ significantly. 
Figure 13. The effect of fluoroquinolone ligands on plasma mobilization of copper. 
 
2.7.2. Nickel in Human Blood Plasma Model 
Earlier works suggested that the major nickel species in blood plasma are Ni(His)2, Ni(Cys)(His), 
Ni(Cys)2 and Ni(His) [51]. Blood nickel levels of 1 × 10−8 mol/L have been reported [52]. The 
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is presented in Table 10. As it can be seen from the data, the FQ with the strongest influence on LMW 
nickel complexes was levofloxacin, even at a concentration of 1 × 10−5 mol/L−1. The calculated distribution 
in the presence of moxifloxacin indicates its relatively lower influence on Ni-LMW species, in a wide 
range of concentrations, compared to Cu-LMW species. The effects of these ligands on the biodistribution 
of Ni-LMW species has the order levofloxacin > ciprofloxacin > ofloxacin > moxifloxacin. 
Table 10. Calculated bio-distribution of dominant Ni (II) species (%) in human blood 
plasma in the presence of fluoroquinolones. 
Ni-LMW Species 
Concentration of Fluoroquinolone (mol/L) 
0 1 × 10−7 1 × 10−5 1 × 10−4 1 × 10−3 
Levofloxacin 
NiHis2 83.2 83.2 73.0 4.9 0.0 
NiCysHis 9.2 9.2 8.0 0.5 0.0 
NiCys2 3.8 3.8 3.4 0.2 0.0 
NiHis 2.4 2.4 2.1 0.1 0.0 
NiHisCit 1.2 1.2 1.1 0.1 0.0 
NiCys 0.1 0.1 0.1 0.0 0.0 
 Ofloxacin 
NiHis2 83.2 83.2 79.7 17.0 0.2 
NiCysHis 9.2 9.2 8.8 1.9 0.0 
NiCys2 3.8 3.8 3.7 0.8 0.0 
NiHis 2.4 2.4 2.3 0.5 0.0 
NiHisCit 1.2 1.2 1.2 0.2 0.0 
NiCys 0.1 0.1 0.1 0.0 0.0 
 Ciprofloxacin 
NiHis2 83.2 83.2 77.5 9.8 0.1 
NiCysHis 9.2 9.2 8.5 1.1 0.0 
NiCys2 3.8 3.8 3.6 0.5 0.0 
NiHis 2.4 2.4 2.2 0.3 0.0 
NiHisCit 1.2 1.2 1.1 0.1 0.0 
NiCys 0.1 0.1 0.1 0.0 0.0 
 Moxifloxacin 
NiHis2 83.2 83.2 83.2 83.0 68.1 
NiCysHis 9.2 9.2 9.1 9.1 7.5 
NiCys2 3.8 3.8 3.8 3.8 3.1 
NiHis 2.4 2.4 2.5 2.4 1.9 
NiHisCit 1.2 1.2 1.2 1.1 1.0 
NiCys 0.1 0.1 1.0 1.0 0.9 
The calculated plasma mobilizing index of nickel in the presence of FQs in shown in Figure 14. 
Levofloxacin shows higher PMI values than the other FQs. This surprisingly high effect may be 
perhaps be useful in the treatment of H. pylori with levofloxacin. 
2.7.3. Zinc in Human Blood Plasma Model 
Since a 35% of total zinc is rigidly bound to the proteins the total concentration of exchangeable 
zinc is estimated to be about 1 × 10−6 mol/L [5]. Calculated distribution of LMW-Zn species is 
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presented in Table 11. At nominal plasma levels, FQs does not exert a significant effect on LMW-Zn 
fractions. It seems that FQs are not effective competitors to amino acids for Zn binding. 
Figure 14. The effect of fluoroquinolone ligands on plasma mobilization of nickel. 
 
Table 11. Calculated bio-distribution of dominant Zn(II) species (%) in human blood 
plasma in the precense of fluoroquinolones. 
Zn-LMW Concentration of Fluoroquinolone (mol/L) 
0 1 × 10−7 1 × 10−5 1 × 10−4 1 × 10−3 
species Moxifloxacin 
ZnCysCit 39.2 39.2 39.2 39.3 38.2 
ZnCys2 19.4 19.4 19.4 19.3 18.3 
ZnCysHis 10.6 10.6 10.6 10.6 10.0 
ZnHis 3.6 3.6 3.6 3.6 3.4 
ZnHCys2 2.7 2.7 2.7 2.7 2.6 
Levofloxacin 
ZnCysCit 39.2 39.2 39.3 39.8 28.2 
ZnCys2 19.4 19.4 19.3 19.0 11.5 
ZnCysHis 10.6 10.6 10.6 10.4 6.0 
ZnHis 3.6 3.6 3.6 3.5 1.9 
ZnHCys2 2.7 2.7 2.7 2.7 1.6 
 Ciprofloxacin 
ZnCysCit 39.2 39.2 39.3 39.5 37.1 
ZnCys2 19.4 19.4 19.4 19.2 16.1 
ZnCysHis 10.6 10.6 10.6 10.5 8.7 
ZnHis 3.6 3.6 3.6 3.6 2.9 
ZnHCys2 2.7 2.7 2.7 2.7 2.3 
 Ofloxacin 
ZnCysCit 39.2 39.2 38.8 35.6 19.7 
ZnCys2 19.4 19.4 19.2 17.8 10.3 
ZnCysHis 10.6 10.6 10.5 9.6 5.2 
ZnHis 3.6 3.6 3.6 3.2 1.6 
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PMI dependence on FQ’s concentration is shown in Figure 15. The FQ’s do not show much 
difference between themselves toward mobilizing power to Zn. 
Figure 15. The effect of fluoroquinolone ligands on plasma mobilization of zinc. 
 
3. Experimental Section  
3.1. Reagents  
Moxifloxacin, (1-cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydropyrolo[3,4-b]pyridine-6-
yl]- 4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride) and ciprofloxacin (1-cyclopropyl-6-
fluoro-4-oxo-7-(piperazin-1-yl)-quinoline-3-carboxylic acid) (declared purities ˃99.9%) were obtained 
from Bayer Pharma AG (Berlin, Germany); ofloxacin (9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-
7-oxo-2,3-dihydro-7H-pyrido-(1,2,3-de)1,4-benzoxazine-6-carboxylic acid) and levofloxacin ((S)-9-
fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxaz-
ine-6-carboxylic acid) (≥99.9% pure) were purchased from Sigma Aldrich (St. Louis, MO, USA). 
Nickel(II) chloride hexahydrate (≥98%, Sigma Aldrich), copper(II) chloride dihydrate (≥99.9%, Sigma 
Aldrich) and zinc(II) chloride hydrate (≥98%, Sigma Aldrich) were utilized. Doubly distilled water 
was used for preparation of all solutions (conductivity less a 0.1 µS cm−1).The solutions of 
fluoroquinolones (5 × 10−3 mol/L) were prepared by direct weighing of standard substances.Metal salts 
were disolved in water with the addition of appropriate amount of HCl to avoid initial hydrolysis of 
metal ions. The concentration were determined by complexometric titration using EDTA and by 
electrogravimetry. The excess of HCl in the metal chloride stock solution was determined 
potentiometrically using Gran’s method. A sodium hydroxide solution was prepared from concentrated 
volumetric solutions (p.a., Merck, NJ, USA), diluted with freshly boiled doubly distilled water 
followed by cooling under a constant flow of purified nitrogen. The alkali concentration was checked 
by titration against potassium hydrogen phthalate. Hydrochloric acid solution was made from HCl 
“Suprapure” (Merck) and standardized against tris(hydroxymethyl) aminomethane. A sodium chloride 
solution was prepared from NaCl, (p.a., Merck), by dissolving the re-crystallized salt in twice-deionized 
water. The concentration of this solution was determined by evaporation of a known volume of 
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providing an inert atmosphere during the titrations, was purified by passing it through 10% NaOH then 
10% H2SO4, alkaline solution of pyrogallol, 0.1 mol/Lsolution of KCl and finally distilled water. 
3.2. Instruments 
Potentiometric measurements were made on a Tacussel Isis 20000 pH meter (Courthezon, 
Vaucluse, France, precision ± 0.1 mV or ± 0.001 pH units) equipped with a Radiometer combined 
electrode. A Metrohm Dosimat model 665 automatic burette with anti-diffusion tip (Herisau, 
Switzerland), was used for delivery of the titrant. 
UV spectral measurements were performed on a double beam UV-Vis spectrophotometer model 
Lambda 35 (PerkinElmer, Waltham, MA, USA). Operational parameters were: scan speed, 2 nm/s, slit 
width, 0.3 nm, photometric sensitivity, 0.2 abs. units. Matching pair of 1 cm quartz cuvettes was used 
for measuring the spectra.  
Fluorescence spectra were collected on Shimadzu RF-1501 spectrofluorimeter (Kyoto, KYT, Japan) 
with a 150 W xenon lamp and 1.0 × 1.0 cm quartz cells. The slit width was set to 10 nm on both the 
excitation and emission monochromators. To ensure reproducible experimental conditions instrument 
performance was checked daily using quinine sulphate solution (4 g/L quinine in 0.5 mol/LH2SO4). 
ESI MS spectra were collected on an LCQ Fleet 3D Ion Trap Mass Spectrometer (Thermo Fisher 
Scientific, Waltham, MA, USA). 1H-NMR spectra were recorded on Varian Gemini 200 spectrometer 
(Palo Alto, CA, USA).  
3.3. Procedure  
3.3.1. Potentiometric Titrations 
Potentiometric titrations were carried out in a double-walled glass vessel, thermostatted at 310 K. 
The ionic strength of all test solutions was adjusted to 0.15 mol/Lwith sodium chloride.  
All measurements were performed under a nitrogen atmosphere. The titration protocol was chosen in 
such a way that the protonation, hydrolysis and complexation reactions would proceed in the 
conditions as close to true equilibrium as possible. Usually stable potential readings were obtained in 
3–5 min after addition of the titrant. If equilibrium could not be established within specified time 
interval the point was discarded. The electrode parameters, E0, Q and Ej from Nernst equation:  
E = E0 + Q logh + Ej were determined by strong acid-strong base titration to check the system 
suitability. During the titrations of the test solutions the E0 and Ej were determined using the data in the 
acidic region where no hydrolysis or complexation takes place (assuming that h is equal to the 
analytical concentration of proton), by plotting E–Q log h against h and extrapolating the straight line 
so obtained to h = 0. The free proton concentration was then calculated through the equation:  
logh = (E – E0 – Ej)/Q which was applied to the whole titration curve. All titrations were carried in 
duplicate. The agreement between duplicate titration was better than 1%. The samples of FQ + metal ion 
solutions were titrated with sodium hydroxide and all titration were performed in the pH range from 2 to 
11 with constant ionic strength (I = 0.15 mol/LNaCl) and under purified nitrogen atmosphere at 310 K. 
Molar ratios between metal ions and fluoroquinolones ranged from 1:1 to 1:2 for all M-FQ systems. 
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3.3.2. Spectrophotometric Measurements 
Spectra of solutions of FQ alone (5 × 10−5 mol/L) and FQ+metal ion in the pH range 2.0–11.0 in 
0.15 mol/LNaCl ionic medium, at 310 K were taken in the wavelength range 250–450 nm. Metal 
concentration was held constant (2.5 × 10−5 mol/L). The pH of all solution was adjusted by the 
addition of 0.1 mol/LHCl or 0.1 mol/LNaOH. Solutions were left for 0.5 h before scanning. Another 
set of spectrophotometric data was performed as spectrophotometric titration. The solution from the 
titration cell was pumped after each addition of alkali to spectrophotometer flow through 10 mm quartz 
cuvette using peristaltic pump. 
3.3.3. Spectrofluorimetric Measurements 
The excitation and emission spectra were taken for either levofloxacin or ofloxacin (2.0 mmol/L) 
with and without presence of copper ion. Aliquots of 0.1 mL of standard solution of either levofloxacin 
or ofloxacin were transferred into 10 mL volumetric flask, using Ependorf pipette and in each flask  
2 mL of phosphate buffer (pH 7.40) and different volumes (0–0.3 mL) of copper ion solution  
(10 mmol/L)) were added. After dilution to the mark with water and thorough mixing, the fluorescence 
intensity of each spectrum was measured in wavelength range 400–650 nm with excitation at 292 nm. 
3.3.4. ESI-MS Measurements 
For ESI-MS measurements FQ-metal solutions were prepared in the FQ to metal ion concentration 
ratio 2:1 at the pH 4.5 adjusted with ammonium formate buffer. Concentration of fluoroquinolone in 
solutions was 2 × 10−4 mol/L. The ESI–source parameters were as follows: source voltage 4.7 kV, 
capillary voltage 23 V, tube lens voltage 90 V, capillary temperature 220 °C, sheath gas flow (N2) 32 
(arbitrary units). ESI-MS spectra were acquired by full range acquisition of m/z 200–2000. The 
normalized collision energy of the CID cell was set at 8–20 eV. 
3.3.5. NMR Measurements  
All 1H-NMR spectra were recorded in DMSO-d6 and in D2O solutions. Typical conditions for  
1H-NMR measurements were: spectral width 3,500 Hz, pulse delay time 1 s, no of scans 72. Chemical 
shifts (δ, ppm) were obtained for 3-trimethylsilylpropionic acid-d4 sodium salt as an internal standard 
(δ = 0.000 ppm).  
3.4. Data Treatment  
The species formed in the studied systems were characterized by the general equilibrium: 
݌ܯଶା + ݍܨܳି + ݎܪା ↔ [MpFQqHr](ଶ௣ା௤ି௥) (13)
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where FQ− is the deprotonated molecule of the ligand. Fully protonated fluoroquinolone is donated as 
H2FQ+. The concentration stability constants of complexes βp,q,r were calculated with the aid of the 
suite of computer programs Hyperquad2006 [17]. In Hyperquad calculations the identity and stability 
of complexes which give the best fit to the experimental data, were determinated by minimizing the 
error squares sum of the potentials, U: U = ∑wi(Eobs − Ecalc)2 where wi represents a statistical weight 
assigned to each point of titration curve, Eobs and Ecalc refer to the measured potential of the cell and 
the calculated one assuming the specific model and trial constants, respectively. Quality of fit was 
judged by usual statistical parameters: Pearsons test, χ2, standard deviation in potential residuals, s, and 
the difference between experimentally determined and calculated standard EMF of the cell. If this 
difference was higher than 1 mV the titration was discarded. The spectrophotometric data were 
evaluated with Hyperquad2006 and pHab2006 programs. The composition, stability and molar 
absorptivities, εp,q,r of complexes were determinated by minimizing the sum, S, defined as:  
S = ∑(Aobs − Acalc)2 where Aobs and Acalc refer to measured absorbance and that calculated according to 
equation: Acalc = ∑ βp,q,r[M]p [FQ]q [H]r εp,q,r. Acceptance criteria for each particular model were: S 
lower than 1.0 × 10−2 and standard deviation of the fit of the spectrum (SD) less than 0.08 units. For 
Hyperquad calculations the spectra were digitized at 2 nm intervals. The final model obtained in 
Hyperquad calculations was optimized. 
3.5. The Human Blood Plasma Model and Speciation Calculation 
In developing the computer model of blood plasma, we updated the May et al. model of blood 
plasma and constructed a model including nine metals, 43 ligands and over 6,100 complexes [5]. The 
free concentration of all metal ions (component) was calculated by solving a mass balance equation 
written for each component: 






൱ × 1ߛ௝ ݅ = 1, 2, 3, … , ݊ (15)
where ܥ௜ is the total analytical concentration of component ݅, [ ௜ܺ] the concentration of free component 
݅, and ݔ௝௜  the stoichiometric factor of component ݅ in species ௝ܵ . The species ௝ܵ  is formed from the 
components A, B, C… according to equations: 
ܽܣ + ܾܤ + ܿܥ +⋯ = ܣ௔ܤ௕ܥ௖ … (16)




where {} denotes activity, and a,b,c… are stoichiometric factors of components A, B, C in species ௝ܵ, 
respectively, and ߚ௝ is the stability constant of ௝ܵ. 
Total concentrations of all components were taken from published papers and Geigy tables [53–63]. 
The stability constants were extracted from the literature and were necessary adjusted to 310 K and 
ionic strength of 0.15 mol/L [64–66]. The equilibrium constants not available in the literature were 
measured in this work or estimated using LFER approach. A complete list of complexes of 
components and constants was described in detail in our previous work [16].  
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4. Conclusions  
Computer simulations are a useful way of predicting the effect of various exogenous ligands on  
the biodistribution of essential metal ions in biological fluids and tissues, particularly in human blood 
plasma. Fluoroquinolones affect to a significant degree the distribution of LMW species of the 
essential metal ions Cu and Zn and the non-essential one Ni. The effect of fluoroquinolones originates 
from their pronounced tendency chelate aforementioned metal ions and compete with their major 
binders in human plasma-amino acids. The quantitative evaluation of the mobilizing effect 
demonstrates that fluoroquinolones are safe regarding their ability to disturb LMW complexation 
equilibria in blood plasma and consequently change the metabolism of Cu, Ni and Zn ions. Thus, the 
amino-acid pool is metal protective in plasma and as computer simulation results show, quinolones 
cannot significantly disturb these equilibria under normal concentration conditions. However, if such 
conditions are (temporarily) changed, for example, after intravenous infusion of the drug the  
metal-quinolone interactions may become noticeable and consequently metal mobilization may take 
place. The observed effect emphasizes the need to take into the consideration not only free quinolones, 
but also metallo-quinolone complexes in any explanation of their antibacterial action. 
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